MX2011005077A - Un metodo para reducir el complejo de lipoproteina-beta-2-glicopro teina 1 de baja densidad oxidado circulante para el tratamiento de ateroesclerosis. - Google Patents
Un metodo para reducir el complejo de lipoproteina-beta-2-glicopro teina 1 de baja densidad oxidado circulante para el tratamiento de ateroesclerosis.Info
- Publication number
- MX2011005077A MX2011005077A MX2011005077A MX2011005077A MX2011005077A MX 2011005077 A MX2011005077 A MX 2011005077A MX 2011005077 A MX2011005077 A MX 2011005077A MX 2011005077 A MX2011005077 A MX 2011005077A MX 2011005077 A MX2011005077 A MX 2011005077A
- Authority
- MX
- Mexico
- Prior art keywords
- oil
- group
- fatty acids
- oxldl
- weight
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 32
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims abstract description 42
- 102000003896 Myeloperoxidases Human genes 0.000 claims abstract description 24
- 108090000235 Myeloperoxidases Proteins 0.000 claims abstract description 24
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 235000021281 monounsaturated fatty acids Nutrition 0.000 claims abstract description 9
- 235000003441 saturated fatty acids Nutrition 0.000 claims abstract description 9
- 150000004671 saturated fatty acids Chemical class 0.000 claims abstract description 9
- 235000014107 unsaturated dietary fats Nutrition 0.000 claims abstract description 5
- 239000003921 oil Substances 0.000 claims description 38
- 235000019198 oils Nutrition 0.000 claims description 38
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 34
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 26
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 25
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 25
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 25
- 239000008162 cooking oil Substances 0.000 claims description 22
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 22
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims description 17
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims description 17
- 239000002775 capsule Substances 0.000 claims description 17
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 17
- 241000195493 Cryptophyta Species 0.000 claims description 14
- 235000019483 Peanut oil Nutrition 0.000 claims description 11
- 239000000312 peanut oil Substances 0.000 claims description 11
- 238000010411 cooking Methods 0.000 claims description 8
- 235000007882 dietary composition Nutrition 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 150000004665 fatty acids Chemical class 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 5
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 5
- 238000009826 distribution Methods 0.000 claims description 5
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 5
- 239000008158 vegetable oil Substances 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 235000019774 Rice Bran oil Nutrition 0.000 claims description 3
- 235000019485 Safflower oil Nutrition 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 235000006708 antioxidants Nutrition 0.000 claims description 3
- 239000000828 canola oil Substances 0.000 claims description 3
- 235000019519 canola oil Nutrition 0.000 claims description 3
- 235000005687 corn oil Nutrition 0.000 claims description 3
- 239000002285 corn oil Substances 0.000 claims description 3
- 239000008157 edible vegetable oil Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000004006 olive oil Substances 0.000 claims description 3
- 235000008390 olive oil Nutrition 0.000 claims description 3
- 239000008165 rice bran oil Substances 0.000 claims description 3
- 235000005713 safflower oil Nutrition 0.000 claims description 3
- 239000003813 safflower oil Substances 0.000 claims description 3
- 239000008159 sesame oil Substances 0.000 claims description 3
- 235000011803 sesame oil Nutrition 0.000 claims description 3
- 235000012424 soybean oil Nutrition 0.000 claims description 3
- 239000003549 soybean oil Substances 0.000 claims description 3
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- 235000013311 vegetables Nutrition 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 38
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 27
- 108010007622 LDL Lipoproteins Proteins 0.000 description 21
- 102000007330 LDL Lipoproteins Human genes 0.000 description 21
- 235000021323 fish oil Nutrition 0.000 description 16
- 230000009467 reduction Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 235000012000 cholesterol Nutrition 0.000 description 12
- 208000029078 coronary artery disease Diseases 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 238000011161 development Methods 0.000 description 8
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 208000032928 Dyslipidaemia Diseases 0.000 description 6
- 208000017170 Lipid metabolism disease Diseases 0.000 description 6
- 230000003143 atherosclerotic effect Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 5
- 235000019486 Sunflower oil Nutrition 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 229940119224 salmon oil Drugs 0.000 description 5
- 239000002600 sunflower oil Substances 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 4
- 108090001030 Lipoproteins Proteins 0.000 description 4
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- ACWBBAGYTKWBCD-ZETCQYMHSA-N 3-chloro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(Cl)=C1 ACWBBAGYTKWBCD-ZETCQYMHSA-N 0.000 description 3
- 206010003178 Arterial thrombosis Diseases 0.000 description 3
- 102000053028 CD36 Antigens Human genes 0.000 description 3
- 108010045374 CD36 Antigens Proteins 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000007214 atherothrombosis Effects 0.000 description 3
- 235000021152 breakfast Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 230000000207 pro-atherogenic effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical class CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 2
- ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000000923 atherogenic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940125753 fibrate Drugs 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 210000000497 foam cell Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000007845 reactive nitrogen species Substances 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 101710099461 Aminopeptidase N Proteins 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 206010002910 Aortic thrombosis Diseases 0.000 description 1
- 101500021168 Aplysia californica Myomodulin-F Proteins 0.000 description 1
- 101150102415 Apob gene Proteins 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 108010038218 Dietary Fish Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- MGKJFRPUFVNFPI-GPHNJDIKSA-N dcid Chemical compound C1=CC=C2[C@@]3(OC(=O)C)[C@]4(OC(C)=O)C5=CC=CC=C5C(=O)[C@@H]4[C@H]3C(=O)C2=C1 MGKJFRPUFVNFPI-GPHNJDIKSA-N 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000013198 immunometric assay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- -1 lipid hydroperoxides Chemical class 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11482308P | 2008-11-14 | 2008-11-14 | |
| PCT/IB2009/007669 WO2010055419A2 (en) | 2008-11-14 | 2009-11-10 | A method of lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011005077A true MX2011005077A (es) | 2011-05-25 |
Family
ID=42170470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011005077A MX2011005077A (es) | 2008-11-14 | 2009-11-10 | Un metodo para reducir el complejo de lipoproteina-beta-2-glicopro teina 1 de baja densidad oxidado circulante para el tratamiento de ateroesclerosis. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9446013B2 (enExample) |
| EP (1) | EP2355812B1 (enExample) |
| JP (2) | JP2012508791A (enExample) |
| KR (1) | KR20110098909A (enExample) |
| CN (1) | CN102202661A (enExample) |
| AU (1) | AU2009315314B2 (enExample) |
| BR (1) | BRPI0915247A2 (enExample) |
| CA (1) | CA2743434C (enExample) |
| DK (1) | DK2355812T3 (enExample) |
| MX (1) | MX2011005077A (enExample) |
| WO (1) | WO2010055419A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
| US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
| US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
| US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
| NO344004B1 (en) * | 2017-06-23 | 2019-08-12 | Olivita As | Combination of oils |
| WO2021080951A1 (en) * | 2019-10-21 | 2021-04-29 | President And Fellows Of Harvard College | Compositions and methods for detection of oxidizable analytes |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8524275D0 (en) * | 1985-10-02 | 1985-11-06 | Efamol Ltd | Pharmaceutical & dietary compositions |
| US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| GB2238476A (en) * | 1989-11-04 | 1991-06-05 | K T Lalvani | Therapeutic aquatic animal and garlic products |
| US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| IT1274734B (it) * | 1994-08-25 | 1997-07-24 | Prospa Bv | Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti |
| US5578334A (en) * | 1995-04-07 | 1996-11-26 | Brandeis University | Increasing the HDL level and the HDL/LDL ratio in human serum with fat blends |
| IT1277953B1 (it) * | 1995-12-21 | 1997-11-12 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per |
| DE19855426A1 (de) * | 1998-12-02 | 2000-06-08 | Wolfgang Langhoff | Mittel zur Therapie und Prophylaxe von rheumatisch-arthritischen Erkrankungen und zur Prophylaxe von cardiovaskulären Erkrankungen |
| JP2001346517A (ja) * | 2000-06-02 | 2001-12-18 | K-Tac Planners Co Ltd | 食用油脂。 |
| DE20105126U1 (de) * | 2001-03-23 | 2002-01-31 | Bartz, Volker, 35440 Linden | Fischöl zur oralen Einnahme |
| GB0210212D0 (en) * | 2002-05-03 | 2002-06-12 | Univ Southampton | Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability |
| EP1501493B1 (en) * | 2002-05-03 | 2009-10-07 | Pronova BioPharma Norge AS | Use of epa and dha in secondary prevention of strokes |
| ES2254018B2 (es) * | 2004-11-16 | 2009-01-01 | Universidad Autonoma De Madrid | Mezcla oleosa de ingredientes bioactivos naturales para la preparacion de un producto alimenticio enriquecido. |
| PT1876906E (pt) * | 2005-04-29 | 2009-12-15 | Vinorica S L | Suplemento alimentar ou alimento funcional contendo uma combinação de óleos |
| US20090252853A1 (en) * | 2005-11-30 | 2009-10-08 | Angel Gil Hernandez | Lipid Mixture and Use Thereof in the Preparation of a Product That Is Intended for Enteral or Oral Administration |
| PL1800675T4 (pl) * | 2005-12-23 | 2012-02-29 | Nutricia Nv | Kompozycja zawierająca wielonienasycone kwasy tłuszczowe, białka, mangan, i/lub molibden oraz nukleozydy/nukleotydy do leczenia otępienia |
| JP5099808B2 (ja) * | 2006-05-29 | 2012-12-19 | 独立行政法人農業・食品産業技術総合研究機構 | 脂質代謝改善用組成物 |
| WO2008088415A1 (en) * | 2006-10-18 | 2008-07-24 | Reliant Pharmaceuticals, Inc. | Omega-3 fatty acids for reduction of lp-pla2 levels |
| US20090270502A1 (en) * | 2007-01-11 | 2009-10-29 | Carotino Sdn. Bhd. | Method for Lowering Risk of Cardiovascular Diseases |
-
2009
- 2009-11-10 CA CA2743434A patent/CA2743434C/en active Active
- 2009-11-10 BR BRPI0915247A patent/BRPI0915247A2/pt not_active Application Discontinuation
- 2009-11-10 MX MX2011005077A patent/MX2011005077A/es active IP Right Grant
- 2009-11-10 DK DK09825826.2T patent/DK2355812T3/da active
- 2009-11-10 EP EP09825826.2A patent/EP2355812B1/en active Active
- 2009-11-10 CN CN2009801442637A patent/CN102202661A/zh active Pending
- 2009-11-10 WO PCT/IB2009/007669 patent/WO2010055419A2/en not_active Ceased
- 2009-11-10 AU AU2009315314A patent/AU2009315314B2/en active Active
- 2009-11-10 JP JP2011543839A patent/JP2012508791A/ja active Pending
- 2009-11-10 US US13/125,806 patent/US9446013B2/en active Active - Reinstated
- 2009-11-10 KR KR1020117013499A patent/KR20110098909A/ko not_active Ceased
-
2015
- 2015-01-08 JP JP2015002682A patent/JP2015091855A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010055419A3 (en) | 2010-09-10 |
| US9446013B2 (en) | 2016-09-20 |
| WO2010055419A2 (en) | 2010-05-20 |
| EP2355812A2 (en) | 2011-08-17 |
| AU2009315314A1 (en) | 2010-05-20 |
| DK2355812T3 (da) | 2019-10-07 |
| KR20110098909A (ko) | 2011-09-02 |
| CA2743434A1 (en) | 2010-05-20 |
| CN102202661A (zh) | 2011-09-28 |
| EP2355812B1 (en) | 2019-07-10 |
| CA2743434C (en) | 2015-04-21 |
| JP2012508791A (ja) | 2012-04-12 |
| US20110207821A1 (en) | 2011-08-25 |
| AU2009315314B2 (en) | 2013-04-18 |
| EP2355812A4 (en) | 2012-04-18 |
| JP2015091855A (ja) | 2015-05-14 |
| BRPI0915247A2 (pt) | 2016-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pettersson et al. | Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: a prospective, double-blind, randomized study | |
| Stalenhoef et al. | The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertrygliceridemia | |
| Harris et al. | Stearidonic acid-enriched soybean oil increased the omega-3 index, an emerging cardiovascular risk marker | |
| Xia et al. | Supplementation of diets with the black rice pigment fraction attenuates atherosclerotic plaque formation in apolipoprotein E deficient mice | |
| Phelps et al. | Garlic supplementation and lipoprotein oxidation susceptibility | |
| Conquer et al. | Effect of supplementation with different doses of DHA on the levels of circulating DHA as non-esterified fatty acid in subjects of Asian Indian background | |
| EP1501493B1 (en) | Use of epa and dha in secondary prevention of strokes | |
| JP2019206552A (ja) | 小児メタボリック症候群を治療する方法 | |
| Kagan et al. | Acute appearance of fatty acids in human plasma–a comparative study between polar-lipid rich oil from the microalgae Nannochloropsis oculata and krill oil in healthy young males | |
| Liu et al. | Protective role of n6/n3 PUFA supplementation with varying DHA/EPA ratios against atherosclerosis in mice | |
| Yamashita et al. | Varying the ratio of dietary n− 6/n− 3 polyunsaturated fatty acid alters the tendency to thrombosis and progress of atherosclerosis in apoE−/− LDLR−/− double knockout mouse | |
| Muñoz et al. | Walnut-enriched diet increases the association of LDL from hypercholesterolemic men with human HepG2 cells | |
| KR20140007973A (ko) | 고중성지방혈증 치료 방법 | |
| AU2009315314B2 (en) | A method of lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosclerosis | |
| AU2004210244C1 (en) | Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of cholesterol and triglycerides | |
| El‐Kirsh et al. | The effect of L‐arginine or L‐citrulline supplementation on biochemical parameters and the vascular aortic wall in high‐fat and high‐cholesterol‐fed rats | |
| Arbonés-Mainar et al. | Accelerated atherosclerosis in apolipoprotein E-deficient mice fed Western diets containing palm oil compared with extra virgin olive oils: a role for small, dense high-density lipoproteins | |
| Nayeri et al. | LDL fatty acids composition as a risk biomarker of cardiovascular disease | |
| JP4688203B2 (ja) | 脳卒中等における二次的な脳疾患事象におけるエイコサペンタエン酸（ｅｐａ）およびドコサヘキサエン酸（ｄｈａ）を使用した薬剤 | |
| Rainwater et al. | Vitamin E dietary supplementation significantly affects multiple risk factors for cardiovascular disease in baboons | |
| HK1158526A (en) | A method of lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosclerosis | |
| 袁興宇 | Study on cholesterol metabolism in lifestyle diseases ameliorated by food functional ingredients | |
| Le | Postprandial Lipoproteins | |
| US20220008435A1 (en) | Therapeutic, preventive, or improvement agent for inflammatory disease and allergic disease | |
| Razak et al. | Neutral effects of Tocotrienol-rich fraction supplementation on serum Lipids, C-reactive protein and Plasma Lipid Peroxidation in rabbits with severe Hypercholesterolaemia and Atherosclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |